75886
document
Hemolytic streptococcus preparation OK-432 ; beneficial adjuvant therapy in recurrent gastric carcinoma . The administration of a hemolytic streptococcus preparation , OK-432 , is thought to be of therapeutic value in the treatment of cancer patients through a stimulatory effect on the immune system . In order to evaluate any beneficial effect of such an administration , a group of patients with recurrent gastric cancer was studied . This group was randomly subdivided into 3 groups : 1 ) Intradermal group ( ID Group ) , 42 patients given an intradermal injections of OK-432 . 2 ) Intramuscular group ( IM Group ) , 40 patients given an intramuscular injections of OK-432 . 3 ) Control group ( C Group ) , 39 patients not given injections . Each group was studied in regards to the length of survival , the host immune response and the incidence of side effects . When compared to the IM and C Groups , the ID Group showed improved survival . Accompanying this improved survival , the ID Group also had greater white cell and lymphocyte counts , a greater number of T cells , and a more dramatic skin reaction to the extracted cell wall polysaccharide of hemolytic streptococcus Su-strain ( Su-PS ) . The ID Group , following OK-432 injection , had a 4.8 % incidence of fever and a 52.4 % incidence of local abscess formation at the injection site . 90 % of the IM Group developed fever but abscess formation was absent in all patients . From these results , it was concluded that in the patients tested , intradermal injection of OK-432 appears to be clinically superior to intramuscular injection .
75887
Intervention_Pharmacological
Hemolytic streptococcus preparation OK-432
75888
Intervention_Pharmacological
hemolytic streptococcus preparation
75889
Intervention_Pharmacological
intradermal injections of OK-432
75890
Intervention_Pharmacological
intramuscular injections of OK-432
75891
Intervention_Control
Control
75892
Outcome_Mortality
length of survival
75893
Outcome_Physical
host immune response
75894
Outcome_Adverse-effects
incidence of side effects
75895
Outcome_Mortality
survival .
75896
Outcome_Physical
white cell and lymphocyte counts
75897
Outcome_Physical
T cells
75898
Outcome_Physical
dramatic skin reaction
75899
Outcome_Physical
fever
75900
Outcome_Physical
local abscess formation
75901
Outcome_Physical
fever
75902
Outcome_Physical
abscess formation
75903
Participant_Condition
recurrent gastric carcinoma .
75904
Participant_Condition
cancer
75905
Participant_Sample-size
42
75906
Participant_Sample-size
40
75907
Participant_Sample-size
39